貝達喹啉 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "貝達喹啉" in Chinese language version.

refsWebsite

Global rank Chinese rank

24web.archive.org

1^st place

15nih.gov

4^th place

5^th place

13doi.org

2^nd place

23^rd place

3drugs.com

399^th place

208^th place

3harvard.edu

18^th place

57^th place

2worldcat.org

5^th place

12^th place

2handle.net

102^nd place

492^nd place

2semanticscholar.org

11^th place

332^nd place

2stoptb.org

low place

2fda.gov

447^th place

581^st place

1rxlist.com

7,927^th place

5,088^th place

1imnotebook.com

low place

1who.int

195^th place

179^th place

1archive.org

6^th place

4^th place

1tballiance.org

low place

1newscientist.com

774^th place

706^th place

1sciencedirect.com

149^th place

292^nd place

1salford.ac.uk

low place

1sequella.com

low place

1go.com

48^th place

146^th place

1nytimes.com

7^th place

31^st place

1wsj.com

79^th place

143^rd place

1bloomberg.com

99^th place

225^th place

1arte.tv

1,950^th place

low place

1theguardian.com

12^th place

60^th place

1msfaccess.org

low place

archive.org

World Health Organization. The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. 2015: 26–30. ISBN 9789241209946. ISSN 0512-3054. hdl:10665/189763 . WHO technical report series;994.

arte.tv

Pinzler J, Mischke T. Die WHO - Im Griff der Lobbyisten?. Arte TV. 2016 [2020-04-08]. （原始内容存档于2020-04-24）.

bloomberg.com

Edney A. J&J&J Sirturo Wins FDA Approval to Treat Drug-Resistant TB. Bloomberg.com (Bloomberg). 2012-12-31 [2013-01-01]. （原始内容存档于2013-01-04）.

doi.org

Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. The New England Journal of Medicine. June 2009, 360 (23): 2397–405. PMID 19494215. doi:10.1056/NEJMoa0808427 .
Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. September 2018, 392 (10150): 821–834. PMC 6463280 . PMID 30215381. doi:10.1016/S0140-6736(18)31644-1 （英语）. 已忽略未知参数|collaborate= (帮助)
Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?. Therapeutic Advances in Chronic Disease. July 2015, 6 (4): 170–84. PMC 4480545 . PMID 26137207. doi:10.1177/2040622315582325.
Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. The New England Journal of Medicine. August 2014, 371 (8): 723–32. PMID 25140958. doi:10.1056/NEJMoa1313865 .
Cox E, Laessig K. FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis. The New England Journal of Medicine. August 2014, 371 (8): 689–91. PMID 25140952. doi:10.1056/NEJMp1314385 .
Yutong Jin, Yutong; Benkeser, David. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation 62 (4). October 2023 [2024-02-28]. doi:10.1016/j.ijantimicag.2023.106939. （原始内容存档于2024-02-28）.
Worley MV, Estrada SJ. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy. November 2014, 34 (11): 1187–97. PMC 5028565 . PMID 25203970. doi:10.1002/phar.1482.
Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nature Communications. February 2014, 5 (1): 3369. Bibcode:2014NatCo...5.3369K. PMC 3948051 . PMID 24569628. doi:10.1038/ncomms4369.
Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLOS ONE. 2014-07-10, 9 (7): e102135. Bibcode:2014PLoSO...9j2135A. PMC 4092087 . PMID 25010492. doi:10.1371/journal.pone.0102135 .
Fiorillo M, Scatena C, Naccarato AG, Sotgia F, Lisanti MP. Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase (PDF). Cell Death and Differentiation. May 2021, 28 (9): 2797–2817 [2024-03-11]. PMC 8408289 . PMID 33986463. S2CID 234496165. doi:10.1038/s41418-021-00788-x. （原始内容存档 (PDF)于2023-04-01）.
Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA. In search of new cures for tuberculosis (PDF). Medicinal Chemistry. May 2007, 3 (3): 301–16 [2024-03-11]. PMID 17504204. doi:10.2174/157340607780620626. （原始内容 (PDF)存档于2020-07-03）.
de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins. June 2007, 67 (4): 971–80. PMID 17387738. S2CID 41795564. doi:10.1002/prot.21376 .
Gotham D, McKenna L, Frick M, Lessem E. Public investments in the clinical development of bedaquiline. PLOS ONE. 18 September 2020, 15 (9): e0239118. Bibcode:2020PLoSO..1539118G. PMC 7500616 . PMID 32946474. doi:10.1371/journal.pone.0239118 .

drugs.com

Bedaquiline Fumarate. The American Society of Health-System Pharmacists. [2016-12-08]. （原始内容存档于2016-12-20）.
Bedaquiline (Sirturo) Use During Pregnancy. www.drugs.com. [2016-12-10]. （原始内容存档于2016-12-20）.
Drugs.com: Sirturo Side Effects 互联网档案馆的存檔，存档日期2013-09-23.

fda.gov

Press Announcements - FDA approves first drug to treat multi-drug resistant tuberculosis. www.fda.gov. Dec 2012. （原始内容存档于2016-12-19）（英语）.

accessdata.fda.gov

Prescribing Information for Bedaquiline (PDF). [2014-04-28]. （原始内容存档 (PDF)于2013-08-24）.

go.com

abcnews.go.com

FDA Approves 1st New Tuberculosis Drug in 40 Years. ABC News. [2012-12-31]. （原始内容存档于2013-01-04）.

handle.net

hdl.handle.net

World Health Organization. The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. 2015: 26–30. ISBN 9789241209946. ISSN 0512-3054. hdl:10665/189763 . WHO technical report series;994.
World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu

ui.adsabs.harvard.edu

Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nature Communications. February 2014, 5 (1): 3369. Bibcode:2014NatCo...5.3369K. PMC 3948051 . PMID 24569628. doi:10.1038/ncomms4369.
Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLOS ONE. 2014-07-10, 9 (7): e102135. Bibcode:2014PLoSO...9j2135A. PMC 4092087 . PMID 25010492. doi:10.1371/journal.pone.0102135 .
Gotham D, McKenna L, Frick M, Lessem E. Public investments in the clinical development of bedaquiline. PLOS ONE. 18 September 2020, 15 (9): e0239118. Bibcode:2020PLoSO..1539118G. PMC 7500616 . PMID 32946474. doi:10.1371/journal.pone.0239118 .

imnotebook.com

Bedaquiline. [2014-04-28]. （原始内容存档于2013-05-20）.

msfaccess.org

MSF demands J&J give up its patent monopoly on TB drug to put lives over profits. Médecins Sans Frontières Access Campaign. 2023-04-26 [2023-07-11]. （原始内容存档于2023-12-17）（英语）.

newscientist.com

Two new drug therapies might cure every form of tuberculosis. New Scientist. （原始内容存档于2017-02-20）.

nih.gov

ncbi.nlm.nih.gov

Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. The New England Journal of Medicine. June 2009, 360 (23): 2397–405. PMID 19494215. doi:10.1056/NEJMoa0808427 .
Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. September 2018, 392 (10150): 821–834. PMC 6463280 . PMID 30215381. doi:10.1016/S0140-6736(18)31644-1 （英语）. 已忽略未知参数|collaborate= (帮助)
Centers for Disease Control Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR. Recommendations and Reports. October 2013, 62 (RR-09): 1–12. PMID 24157696.
WHO. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance.. World Health Organization. 2013. （原始内容存档于2017-09-10）.
Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?. Therapeutic Advances in Chronic Disease. July 2015, 6 (4): 170–84. PMC 4480545 . PMID 26137207. doi:10.1177/2040622315582325.
Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. The New England Journal of Medicine. August 2014, 371 (8): 723–32. PMID 25140958. doi:10.1056/NEJMoa1313865 .
Isralls, Sharon; Kathy, Baisley. QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study. Open Forum Infectious Diseases. August 2021,. 8(8): ofab413. (8): ofab413 [2024-02-28]. （原始内容存档于2024-02-28）.
Cox E, Laessig K. FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis. The New England Journal of Medicine. August 2014, 371 (8): 689–91. PMID 25140952. doi:10.1056/NEJMp1314385 .
Worley MV, Estrada SJ. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy. November 2014, 34 (11): 1187–97. PMC 5028565 . PMID 25203970. doi:10.1002/phar.1482.
Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nature Communications. February 2014, 5 (1): 3369. Bibcode:2014NatCo...5.3369K. PMC 3948051 . PMID 24569628. doi:10.1038/ncomms4369.
Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLOS ONE. 2014-07-10, 9 (7): e102135. Bibcode:2014PLoSO...9j2135A. PMC 4092087 . PMID 25010492. doi:10.1371/journal.pone.0102135 .
Fiorillo M, Scatena C, Naccarato AG, Sotgia F, Lisanti MP. Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase (PDF). Cell Death and Differentiation. May 2021, 28 (9): 2797–2817 [2024-03-11]. PMC 8408289 . PMID 33986463. S2CID 234496165. doi:10.1038/s41418-021-00788-x. （原始内容存档 (PDF)于2023-04-01）.
Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA. In search of new cures for tuberculosis (PDF). Medicinal Chemistry. May 2007, 3 (3): 301–16 [2024-03-11]. PMID 17504204. doi:10.2174/157340607780620626. （原始内容 (PDF)存档于2020-07-03）.
de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins. June 2007, 67 (4): 971–80. PMID 17387738. S2CID 41795564. doi:10.1002/prot.21376 .
Gotham D, McKenna L, Frick M, Lessem E. Public investments in the clinical development of bedaquiline. PLOS ONE. 18 September 2020, 15 (9): e0239118. Bibcode:2020PLoSO..1539118G. PMC 7500616 . PMID 32946474. doi:10.1371/journal.pone.0239118 .

nytimes.com

Thomas K. F.D.A. Approves New Tuberculosis Drug. The New York Times. 2012-12-31 [2012-12-31]. （原始内容存档于2013-01-08）.

rxlist.com

Sirturo: Clinical Pharmacology. [2014-04-28]. （原始内容存档于2015-02-28）.

salford.ac.uk

usir.salford.ac.uk

Fiorillo M, Scatena C, Naccarato AG, Sotgia F, Lisanti MP. Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase (PDF). Cell Death and Differentiation. May 2021, 28 (9): 2797–2817 [2024-03-11]. PMC 8408289 . PMID 33986463. S2CID 234496165. doi:10.1038/s41418-021-00788-x. （原始内容存档 (PDF)于2023-04-01）.

sciencedirect.com

Yutong Jin, Yutong; Benkeser, David. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation 62 (4). October 2023 [2024-02-28]. doi:10.1016/j.ijantimicag.2023.106939. （原始内容存档于2024-02-28）.

semanticscholar.org

api.semanticscholar.org

Fiorillo M, Scatena C, Naccarato AG, Sotgia F, Lisanti MP. Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase (PDF). Cell Death and Differentiation. May 2021, 28 (9): 2797–2817 [2024-03-11]. PMC 8408289 . PMID 33986463. S2CID 234496165. doi:10.1038/s41418-021-00788-x. （原始内容存档 (PDF)于2023-04-01）.
de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins. June 2007, 67 (4): 971–80. PMID 17387738. S2CID 41795564. doi:10.1002/prot.21376 .

sequella.com

Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA. In search of new cures for tuberculosis (PDF). Medicinal Chemistry. May 2007, 3 (3): 301–16 [2024-03-11]. PMID 17504204. doi:10.2174/157340607780620626. （原始内容 (PDF)存档于2020-07-03）.

stoptb.org

UNOPS. Stop TB Partnership, Global Drug Facility (GDF), The Bedaquiline Donation Program. www.stoptb.org. 2015 [2020-04-08]. （原始内容存档于2020-06-11）（英语）.
Global Drug Facility Update on Access to Bedaquiline | Stop TB Partnership. [2024-03-11]. （原始内容存档于2024-03-09）.

tballiance.org

BPaMZ. TB Alliance. 2016-07-12. （原始内容存档于2017-02-19）.

theguardian.com

Dhillon, Amrit. Victory over big pharma opens door to cheaper tuberculosis drugs. The Guardian. 2023-03-29 [2023-07-11]. ISSN 0261-3077. （原始内容存档于2024-02-21）（英国英语）.

web.archive.org

Bedaquiline Fumarate. The American Society of Health-System Pharmacists. [2016-12-08]. （原始内容存档于2016-12-20）.
Sirturo: Clinical Pharmacology. [2014-04-28]. （原始内容存档于2015-02-28）.
Bedaquiline. [2014-04-28]. （原始内容存档于2013-05-20）.
WHO Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). WHO. [2019-04-24]. （原始内容存档于2018-08-20）.
Bedaquiline (Sirturo) Use During Pregnancy. www.drugs.com. [2016-12-10]. （原始内容存档于2016-12-20）.
Press Announcements - FDA approves first drug to treat multi-drug resistant tuberculosis. www.fda.gov. Dec 2012. （原始内容存档于2016-12-19）（英语）.
WHO. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance.. World Health Organization. 2013. （原始内容存档于2017-09-10）.
BPaMZ. TB Alliance. 2016-07-12. （原始内容存档于2017-02-19）.
Two new drug therapies might cure every form of tuberculosis. New Scientist. （原始内容存档于2017-02-20）.
Drugs.com: Sirturo Side Effects 互联网档案馆的存檔，存档日期2013-09-23.
Prescribing Information for Bedaquiline (PDF). [2014-04-28]. （原始内容存档 (PDF)于2013-08-24）.
Isralls, Sharon; Kathy, Baisley. QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study. Open Forum Infectious Diseases. August 2021,. 8(8): ofab413. (8): ofab413 [2024-02-28]. （原始内容存档于2024-02-28）.
Yutong Jin, Yutong; Benkeser, David. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation 62 (4). October 2023 [2024-02-28]. doi:10.1016/j.ijantimicag.2023.106939. （原始内容存档于2024-02-28）.
Fiorillo M, Scatena C, Naccarato AG, Sotgia F, Lisanti MP. Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase (PDF). Cell Death and Differentiation. May 2021, 28 (9): 2797–2817 [2024-03-11]. PMC 8408289 . PMID 33986463. S2CID 234496165. doi:10.1038/s41418-021-00788-x. （原始内容存档 (PDF)于2023-04-01）.
Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA. In search of new cures for tuberculosis (PDF). Medicinal Chemistry. May 2007, 3 (3): 301–16 [2024-03-11]. PMID 17504204. doi:10.2174/157340607780620626. （原始内容 (PDF)存档于2020-07-03）.
FDA Approves 1st New Tuberculosis Drug in 40 Years. ABC News. [2012-12-31]. （原始内容存档于2013-01-04）.
Thomas K. F.D.A. Approves New Tuberculosis Drug. The New York Times. 2012-12-31 [2012-12-31]. （原始内容存档于2013-01-08）.
Walker J, Tadena N. J&J Tuberculosis Drug Gets Fast-Track Clearance. Wall Street Journal. 2012-12-31 [2013-01-01]. （原始内容存档于2015-09-23）.
Edney A. J&J&J Sirturo Wins FDA Approval to Treat Drug-Resistant TB. Bloomberg.com (Bloomberg). 2012-12-31 [2013-01-01]. （原始内容存档于2013-01-04）.
Pinzler J, Mischke T. Die WHO - Im Griff der Lobbyisten?. Arte TV. 2016 [2020-04-08]. （原始内容存档于2020-04-24）.
UNOPS. Stop TB Partnership, Global Drug Facility (GDF), The Bedaquiline Donation Program. www.stoptb.org. 2015 [2020-04-08]. （原始内容存档于2020-06-11）（英语）.
Dhillon, Amrit. Victory over big pharma opens door to cheaper tuberculosis drugs. The Guardian. 2023-03-29 [2023-07-11]. ISSN 0261-3077. （原始内容存档于2024-02-21）（英国英语）.
MSF demands J&J give up its patent monopoly on TB drug to put lives over profits. Médecins Sans Frontières Access Campaign. 2023-04-26 [2023-07-11]. （原始内容存档于2023-12-17）（英语）.
Global Drug Facility Update on Access to Bedaquiline | Stop TB Partnership. [2024-03-11]. （原始内容存档于2024-03-09）.

who.int

WHO Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). WHO. [2019-04-24]. （原始内容存档于2018-08-20）.

worldcat.org

World Health Organization. The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. 2015: 26–30. ISBN 9789241209946. ISSN 0512-3054. hdl:10665/189763 . WHO technical report series;994.
Dhillon, Amrit. Victory over big pharma opens door to cheaper tuberculosis drugs. The Guardian. 2023-03-29 [2023-07-11]. ISSN 0261-3077. （原始内容存档于2024-02-21）（英国英语）.

wsj.com

Walker J, Tadena N. J&J Tuberculosis Drug Gets Fast-Track Clearance. Wall Street Journal. 2012-12-31 [2013-01-01]. （原始内容存档于2015-09-23）.